Anixa Biosciences, Inc. (ANIX)

US — Healthcare Sector
Peers: ENTX  INO  HURA  IRD  ABOS  VTGN  SEER  SPRO  ACTU  AGEN 

Automate Your Wheel Strategy on ANIX

With Tiblio's Option Bot, you can configure your own wheel strategy including ANIX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ANIX
  • Rev/Share 0.0
  • Book/Share 0.4298
  • PB 6.272
  • Debt/Equity 0.0135
  • CurrentRatio 8.0768
  • ROIC -0.8267

 

  • MktCap 97801935.0
  • FreeCF/Share -0.221
  • PFCF -13.6347
  • PE -8.7023
  • Debt/Assets 0.0127
  • DivYield 0
  • ROE -0.6655

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation ANIX Maxim Group -- Buy -- $10 March 21, 2025

News

Anixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading Interview
ANIX
Published: February 14, 2025 by: PRNewsWire
Sentiment: Neutral

SAN JOSE, Calif. , Feb. 14, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and CEO, Dr. Amit Kumar, was featured in an interview with Alpha Wolf Trading.

Read More
image for news Anixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading Interview

About Anixa Biosciences, Inc. (ANIX)

  • IPO Date 1983-10-07
  • Website https://www.anixa.com
  • Industry Biotechnology
  • CEO Amit Kumar
  • Employees 5
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.